Journal ArticleDOI
Cancer immunotherapy targeting the CD47/SIRPα axis
TLDR
The potential applications of CD47/SIRPα blocking therapies extend beyond human cancer, and may be useful for the treatment of infectious disease, conditioning for stem cell transplant, and many other clinical indications.About:
This article is published in European Journal of Cancer.The article was published on 2017-05-01. It has received 245 citations till now. The article focuses on the topics: Immune checkpoint & Cancer immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
Yuxin Lin,Jianxin Xu,Huiyin Lan +2 more
TL;DR: The regulating networks of TAM polarization and the mechanisms underlying TAM-facilitated metastasis are summarized and the potential applications of TAM-focused therapeutic strategies in clinical cancer treatment at present and in the future are discussed.
Journal ArticleDOI
Human chimeric antigen receptor macrophages for cancer immunotherapy.
Michael Klichinsky,Marco Ruella,Olga Shestova,Xueqing Maggie Lu,Andrew Best,Martha Zeeman,Maggie Schmierer,Konrad Gabrusiewicz,Nicholas R. Anderson,Nicholas E. Petty,Katherine D. Cummins,Feng Shen,Xinhe Shan,Kimberly Veliz,Kristin Blouch,Yumi Yashiro-Ohtani,Saad S. Kenderian,Saad S. Kenderian,Miriam Y. Kim,Miriam Y. Kim,Roddy S. O’Connor,Stephen R. Wallace,Miroslaw Kozlowski,Dylan M. Marchione,Maksim Shestov,Benjamin A. Garcia,Carl H. June,Saar Gill +27 more
TL;DR: It is found that a chimeric adenoviral vector overcame the inherent resistance of primary human macrophages to genetic manipulation and imparted a sustained pro-inflammatory (M1) phenotype in humanized mice.
Journal ArticleDOI
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo,Bhagirathbhai Dholaria,Aixa E. Soyano,Keith L. Knutson,Saranya Chumsri,Yanyan Lou +5 more
TL;DR: A comprehensive review of immune checkpoint pathways involved in cancer immunotherapy is provided, and their mechanisms and the therapeutic interventions currently under investigation in phase I/II clinical trials are discussed.
Journal ArticleDOI
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Amira A. Barkal,Kipp Weiskopf,Kipp Weiskopf,Kevin S. Kao,Sydney Gordon,Benyamin Rosental,Ying Y. Yiu,Benson M. George,Maxim Markovic,Nan Guo Ring,Jonathan M. Tsai,Mckenna Kelly Marie,Po Yi Ho,Robin Z. Cheng,James Y. Chen,Layla J. Barkal,Aaron M. Ring,Irving L. Weissman,Roy Louis Maute +18 more
TL;DR: A central role is found for major histocompatibility complex (MHC) class I in controlling the phagocytic function of macrophages in cancer cells and a novel ‘don’t eat me’ system based on recognition of MHC class I by thephagocyte-expressed inhibitory molecule LILRB1 is identified.
Journal ArticleDOI
Tumor microenvironment as a therapeutic target in cancer
TL;DR: Current progress in targeting the tumor microenvironment in both drug development and clinical trials is summarized and challenges are highlighted to achieve therapeutic efficacy and strategies to intervene in the pro-tumor microenvironment are discussed.
References
More filters
Journal ArticleDOI
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Taro Kawai,Shizuo Akira +1 more
TL;DR: Recent advances that have been made by research into the role of TLR biology in host defense and disease are described.
Journal ArticleDOI
Protective and pathogenic functions of macrophage subsets
Peter J. Murray,Thomas A. Wynn +1 more
TL;DR: The four stages of orderly inflammation mediated by macrophages are discussed: recruitment to tissues; differentiation and activation in situ; conversion to suppressive cells; and restoration of tissue homeostasis.
Journal ArticleDOI
The M1 and M2 paradigm of macrophage activation: time for reassessment.
TL;DR: How cytokines and pathogen signals influence macrophages' functional phenotypes and the evidence for M1 and M2 functions is assessed and a paradigm initially based on the role of a restricted set of selected ligands in the immune response is revisited.
Journal ArticleDOI
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Jonathan C. W. Edwards,Leszek Szczepanski,Jacek Szechiński,Anna Filipowicz-Sosnowska,Paul Emery,D. Close,Randall M Stevens,T. Shaw +7 more
TL;DR: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotRexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Journal ArticleDOI
Role of CD47 as a marker of self on red blood cells.
Per-Arne Oldenborg,Alex Zheleznyak,Yi-Fu Fang,Carl F. Lagenaur,Hattie D. Gresham,Frederik P. Lindberg +5 more
TL;DR: It is shown that CD47 (integrin-associated protein) functions as a marker of self on murine red blood cells and may represent a potential pathway for the control of hemolytic anemia.
Related Papers (5)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham,Jens Peter Volkmer,Andrew J. Gentles,Debashis Sahoo,Piero Dalerba,Siddhartha Mitra,Jian Wang,Humberto Contreras-Trujillo,Robin Martin,Justin D. Cohen,Patricia Lovelace,Ferenc A. Scheeren,Mark P. Chao,Kipp Weiskopf,Chad Tang,Anne Kathrin Volkmer,Tejaswitha J. Naik,Theresa A. Storm,Adriane Mosley,Badreddin Edris,Seraina Schmid,Chris K. Sun,Mei-Sze Chua,Oihana Murillo,Pradeep S. Rajendran,Adriel C. Cha,Robert K. Chin,Dongkyoon Kim,Maddalena Adorno,Tal Raveh,Diane Tseng,Siddhartha Jaiswal,Per Øyvind Enger,Gary K. Steinberg,Gordon Li,Samuel So,Ravindra Majeti,Griffith R. Harsh,Matt De Van Rijn,Nelson N.H. Teng,John B. Sunwoo,Ash A. Alizadeh,Michael F. Clarke,Irving L. Weissman +43 more
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao,Ash A. Alizadeh,Chad Tang,June Helen Myklebust,June Helen Myklebust,Bindu Varghese,Saar Gill,Max Jan,Adriel C. Cha,Charles Chan,Brent T. Tan,Christopher Y. Park,Feifei Zhao,Holbrook E Kohrt,Raquel Malumbres,Javier Briones,Randy D. Gascoyne,Izidore S. Lossos,Ronald Levy,Irving L. Weissman,Ravindra Majeti +20 more